Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with mantle cell lymphoma (a type of blood cancer), confirmed through a tissue sample test
• People whose mantle cell lymphoma responded to first-line treatment — either fully (complete response) or partially (partial response) — after receiving at least 4 cycles of treatment that included a type of drug called a CD20 antibody (such as rituximab-based combinations)
• People who have previously had an autologous stem cell transplant (using their own stem cells) are still able to be considered
• People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning able to carry out daily activities, possibly with some limitations)
• People whose blood, liver, kidney, and heart function all meet specific healthy minimum levels as measured by blood tests and a heart ultrasound (confirm exact values with trial site)
• People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

• People with a known allergy to human or mouse monoclonal antibodies, or to a specific drug called Zanubrutinib or any of its ingredients
• People who have had major surgery in the 4 weeks before joining the trial (routine diagnostic procedures are not included)
• People with serious ongoing health conditions that are not well controlled, including severe infections, significant heart failure, poorly controlled irregular heartbeat, uncontrolled high blood pressure, unstable chest pain, active stomach ulcers, or bleeding disorders
• People with other serious health conditions that would interfere with standard treatment
• People with a history of another active cancer, except for certain skin cancers or early-stage cervical cancer that were treated with curative intent and have not come back within the past 3 years
• People with known active interstitial pneumonia (a type of lung inflammation)
• People with a known history of alcohol or drug misuse
• People with an active hepatitis B infection (based on a virus level blood test); people with past or inactive hepatitis B may still be considered if virus levels are undetectable, provided they agree to regular monitoring and antiviral treatment as required (confirm with trial site)
• People with active hepatitis C infection, unless a specific virus RNA test comes back negative
• People with active HIV or syphilis infections
• People who are pregnant or currently breastfeeding
• People who have received a live vaccine within 4 weeks before the trial treatment begins (standard inactivated flu vaccines are generally allowed)
• People currently taking corticosteroid medicines (such as prednisone) at a dose greater than 30mg per day for 10 or more days continuously
• People who have needed ongoing systemic (whole-body) treatment for an active autoimmune disease within the past 2 years (some exceptions may apply, such as people who only need hormone replacement or thyroid medication — confirm with trial site)
• People who have difficulty swallowing and cannot reliably take oral medication long-term
• People with a mental health condition that affects their ability to follow the trial requirements or give informed consent
• People the trial investigators determine are otherwise not suitable for the study

Important: Always verify eligibility with the trial site directly before applying.